Marshall Wace North America’s Enanta Pharmaceuticals ENTA Stock Holding History

Marshall Wace North America’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-12,761	Closed	-$584K	–	1377
2020 Q3	$584K	Buy	12,761 +3,255	+34%	+$158K	﹤0.01%	933
2020 Q2	$478K	Sell	9,506 -7,957	-46%	-$412K	﹤0.01%	931
2020 Q1	$897K	Buy	17,463 +462	+3%	+$24.6K	0.01%	631
2019 Q4	$1.05M	Sell	17,001 -39,451	-70%	-$2.45M	0.01%	709
2019 Q3	$3.39M	Buy	56,452 +1,025	+2%	+$76.1K	0.02%	437
2019 Q2	$4.68M	Sell	55,427 -170,267	-75%	-$15.3M	0.03%	379
2019 Q1	$21.6M	Buy	225,694 +207,326	+1,129%	+$18.6M	0.15%	138
2018 Q4	$1.3M	Buy	+18,368	New	+$1.41M	0.01%	545
2013 Q4	$1.37M	Buy	+50,097	New	+$1.21M	0.03%	348

Other funds holding ENTA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

KAM

Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Marshall Wace North America's ENTA Position: Q4 2020 in Review

Marshall Wace North America sold out of Enanta Pharmaceuticals (ENTA) in Q4 2020, closing a stake of 12,761 shares — an estimated $584K sold.

Marshall Wace North America first reported a position in ENTA in Q4 2013 and held it in 9 quarters. The position peaked at $21.6M in Q1 2019. 151 funds tracked by Wall St. Rank hold ENTA as of Q4 2020.

Marshall Wace North America reported no remaining Enanta Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
Marshall Wace North America sold 12,761 Enanta Pharmaceuticals shares in Q4 2020, an estimated $584K.
Marshall Wace North America first reported a position in Enanta Pharmaceuticals in Q4 2013 and held it in 9 quarters.
Marshall Wace North America's Enanta Pharmaceuticals position peaked at $21.6M in Q1 2019.
151 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q4 2020.

Based on Marshall Wace North America's 13F filing for Q4 2020, filed 16 Feb 2021.